Trial reportAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2012
Association of factor V gene polymorphism with arteriovenous graft failure.
Trial report in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Antiplatelet agents for chronic kidney disease.The Cochrane database of systematic reviews · 2022Pooled it
- Pooled it
- Development of a prediction model to estimate short- and long-term clinical outcomes in arteriovenous grafts for hemodialysis patients.European journal of medical research · 2025Article
- Article
- Future research directions to improve fistula maturation and reduce access failure.Seminars in vascular surgery · 2016Review
- The molecular mechanisms of hemodialysis vascular access failure.Kidney international · 2016Review
- A Patient with Recurrent Arteriovenous Graft Thrombosis.Clinical journal of the American Society of Nephrology : CJASN · 2015Article
- Candidate Gene Analysis of Mortality in Dialysis Patients.PloS one · 2015Article
- Single nucleotide variants in the protein C pathway and mortality in dialysis patients.PloS one · 2014Article
- Correlation of pre-existing vascular pathology with arteriovenous graft outcomes in hemodialysis patients.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2013Observational
- Candidate gene analysis of arteriovenous fistula failure in hemodialysis patients.Clinical journal of the American Society of Nephrology : CJASN · 2013Article
- Vascular access today.World journal of nephrology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundDialysis grafts fail due to recurrent stenosis and thrombosis. Vasoactive and prothrombotic substances affecting intimal hyperplasia or thrombosis may modify graft outcomes. STUDY
designGenetic polymorphisms association study of patients enrolled in a multicenter randomized clinical trial. SETTING &
participants354 Dialysis Access Consortium (DAC) Study patients receiving a new graft with DNA samples obtained. Participants were randomly assigned to treatment with aspirin plus dipyridamole versus placebo. PREDICTOR: DNA sequence polymorphisms for the following candidate genes and their interaction with the study intervention: methylenetetrahydrofolate reductase (MTHFR), heme oxygenase 1 (HO-1), factor V (F5), transforming growth factor β1 (TGFβ1), klotho, nitric oxide synthase (NOS), and angiotensin-converting enzyme (ACE). OUTCOME: Graft failure (>50% stenosis, angioplasty, thrombosis, surgical intervention, or permanent loss of function).
resultsDuring a median patient follow-up of 34.3 months, 304 grafts failed. After adjusting for clinical factors (patient age, sex, access location, diabetes, cardiovascular disease, baseline aspirin use, body mass index, timing of graft placement, and study treatment) and genetic ancestral background, single-nucleotide polymorphism rs6019 of the factor V gene was associated significantly with graft failure in a dominant model (HR of 1.70 [95% CI, 1.32-2.19; P < 0.001] for G/C and G/G genotypes vs C/C genotypes). There was no significant association between graft failure and polymorphisms of MTHFR, HO-1, TGFβ1, klotho, NOS, or ACE. LIMITATIONS: Small sample size.
conclusionThe rs6019 genotype of Factor V is associated with increased risk of graft failure. Anticoagulation may reduce graft failure in patients with the G/C or G/G genotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.